查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542937

全球數位乳房斷層合成市場 - 2024-2031

Global Digital Breast Tomosynthesis Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球數位乳房斷層合成市場將於 2023 年達到 35 億美元，預計到 2031 年將達到 62 億美元，2024-2031 年預測期間複合年成長率為 7.5%

數位乳房斷層合成，也稱為3D 乳房X 光攝影，是一種檢測乳癌（尤其是緻密乳房組織）的高效方法，它使用一系列2D影像來創建3D影像，這與依賴2D 影像的標準乳房X 光攝影不同。

數位乳房斷層合成 (DBT) 使用 X 光管從多個角度拍攝乳房的多個 2D 影像。此過程類似於標準乳房X光檢查，但乳房被定位並壓縮成弧形。然後這些圖像被數位化並組合成 3D 圖像，從而提供更詳細的資訊，從而更容易區分健康組織和潛在的癌組織。這種方法提供了更準確、更詳細的乳房視圖，增強了乳癌篩檢的診斷能力。

市場動態：

驅動程式和限制

乳癌盛行率上升

全球乳癌發生率的上升增加了對數位乳房斷層合成 (DBT) 等先進診斷工具的需求。 DBT 提供比傳統乳房 X 光攝影檢查更詳細的影像，能夠及早發現細微病變。這種增強的檢測對於早期介入、改善患者治療結果和降低死亡率至關重要。因此，對 DBT 系統的需求激增。

例如，世衛組織發布了新的全球乳癌計劃框架，旨在到2040年拯救25億乳癌患者的生命。乳癌是最常見的成人癌症，95% 的國家將其列為女性癌症死亡的主要原因。然而，生存仍然不公平，80% 的死亡發生在低收入和中等收入國家。

與設備相關的挑戰

數位乳房斷層合成 (DBT) 市場面臨多項挑戰，包括高成本、放射科醫生的專門培訓、潛在的輻射暴露問題、監管障礙和有限的報銷政策。這些因素可能會阻礙 DBT 的成長和採用，特別是在較小的醫療機構和發展中地區。

細分市場分析

全球數位乳房斷層合成市場根據產品類型、應用、最終用戶和地區進行細分。

此產品類型細分市場的2D/3D組合系統約佔數位乳房斷層合成市場佔有率的54.1%

產品類型細分中的2D/3D組合系統約佔54.1%。 2D/3D 組合系統在數位乳房斷層合成 (DBT) 中對於改善乳癌篩檢和診斷至關重要。這些系統將傳統的 2D 乳房 X 光攝影與先進的 3D 斷層合成相結合，提供乳房組織的全面視圖。

這種組合可以提高檢測率，尤其是在緻密的乳房組織中，並減少誤報。它還可以最大限度地減少回電和患者的焦慮。這些系統在臨床環境中越來越受到青睞，因為它們能夠在單次檢查中提供標準的乳房X光攝影視圖和增強的診斷能力。

例如，2023 年 11 月，GE HealthCare 推出了 MyBreastAI Suite，這是一款一體化的人工智慧應用平台，旨在幫助臨床醫生進行乳癌檢測並提高工作流程生產力。該套件整合了三個 iCAD 應用程式：用於 DBT 的 ProFound AI、用於 2D 乳房 X 光攝影的 SecondLook 和 PowerLook 密度評估。

市場地域佔有率

預計北美在整個預測期內將佔據總市場佔有率的 38.4% 左右

由於乳癌發病率上升、FDA 批准、該地區發達的醫療基礎設施、醫療保健支出增加以及其他因素幫助北美市場預計將維持其在整個預測期內的總市場佔有率，北美預計將佔據約38.4% 的市場佔有率。

例如，2023 年11 月，美國食品藥物管理局(FDA) 批准了Lunit Insight DBT 的510(k) 許可，這是一種支援人工智慧(AI) 的模式，可提供數位乳房斷層合成(DBT)影像的輔助評估。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 乳癌盛行率上升
      • 設備的進步
    • 限制
      • 與設備相關的挑戰
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 專利分析
  • 大環境分析
  • SWOT分析
  • DMI 意見

第 6 章：依產品類型

  • 2D/3D 組合系統
  • 獨立 3D 系統

第 7 章：按申請

  • 放映
  • 診斷

第 8 章：最終用戶

  • 醫院
  • 診斷中心
  • 其他

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Fujifilm
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • GE Healthcare
  • GMM (IMS Giotto)
  • Hologic, Inc
  • Planmeca (Planmed)
  • Siemens Healthineers
  • Philips Healthcare
  • Afga Healthcare
  • Trivitron Healthcare
  • Carestream Health (*LIST NOT EXHAUSTIVE)

第 12 章：附錄

簡介目錄
Product Code: MD990

Report Overview

Global Digital Breast Tomosynthesis Market reached US$ 3.5 billion in 2023 and is expected to reach US$ 6.2 billion by 2031, growing at a CAGR of 7.5% during the forecast period 2024-2031

Digital breast tomosynthesis, also known as 3D mammography, is a highly effective method for detecting breast cancer, particularly in dense breast tissue, using a series of two-dimensional images to create a three-dimensional image, unlike standard mammography which relies on 2D images.

Digital breast tomosynthesis (DBT) uses an X-ray tube to take multiple 2D images of the breast from multiple angles. This process is similar to a standard mammogram but with the breast being positioned and compressed in an arc. The images are then digitized and combined into a 3D image, which provides more detailed information, making it easier to distinguish between healthy and potentially cancerous tissue. This method offers a more accurate and detailed view of the breast, enhancing the diagnostic capabilities of breast cancer screening.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of breast cancer

The rise in breast cancer globally has heightened the need for advanced diagnostic tools like Digital Breast Tomosynthesis (DBT). DBT offers more detailed imaging than traditional mammography, enabling early detection of subtle lesions. This enhanced detection is crucial for early intervention, improving patient outcomes, and reducing mortality rates. As a result, the demand for DBT systems has surged.

For instance, WHO has released a new Global Breast Cancer Initiative Framework, aiming to save 2.5 billion lives from breast cancer by 2040. The framework recommends early detection, timely diagnosis, and comprehensive management of the disease. Breast cancer is the most common adult cancer, with 95% of countries having it as the leading cause of female cancer deaths. However, survival remains inequitable, with 80% of deaths occurring in low- and middle-income countries.

Challenges associated with the devices

The Digital Breast Tomosynthesis (DBT) market faces several challenges, including high costs, specialized training for radiologists, potential radiation exposure concerns, regulatory hurdles, and limited reimbursement policies. These factors can hinder the growth and adoption of DBT, especially in smaller healthcare facilities and developing regions.

Market Segment Analysis

The global digital breast tomosynthesis market is segmented based on product type, application, end-user, and region.

The 2D/3D combination systems from the product type segment accounted for approximately 54.1% of the digital breast tomosynthesis market share

The 2D/3D combination systems from the product type segment accounted for approximately 54.1%. 2D/3D combination systems are essential in Digital Breast Tomosynthesis (DBT) for improving breast cancer screening and diagnosis. These systems combine traditional 2D mammography with advanced 3D tomosynthesis, providing a comprehensive view of breast tissue.

This combination leads to better detection rates, especially in dense breast tissue, and reduces false positives. It also minimizes callbacks and patient anxiety. These systems are increasingly preferred in clinical settings due to their ability to provide standard mammographic views and enhanced diagnostic capabilities in a single examination.

For instance, in November 2023, GE HealthCare launched MyBreastAI Suite, an all-in-one platform of AI apps, designed to aid clinicians in breast cancer detection and enhance workflow productivity. The suite integrates three iCAD applications, ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to rising breast cancer incidence, FDA clearance, the region's developed healthcare infrastructure, increasing healthcare spending and other factors help the North American market is expected to maintain its dominance over the forecast period.

For instance, in November 2023, the Food and Drug Administration (FDA) granted 510(k) clearance for Lunit Insight DBT, an artificial intelligence (AI)-enabled modality that provides an adjunctive assessment of digital breast tomosynthesis (DBT) images.

Market Segmentation

By Product Type

  • 2D/3D Combination systems
  • Standalone 3D Systems

By Application

  • Screenings
  • Diagnostic

By End User

  • Hospitals
  • Diagnostic Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Market Competitive Landscape

The major global players in the market include Fujifilm, GE Healthcare, GMM (IMS Giotto), Hologic, Inc., Planmeca (Planmed), Siemens Healthineers, Philips Healthcare, AGFA Healthcare, Trivitron Healthcare, Carestream Health among others.

Key Developments

  • In July 2024, LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic monitors with the new 21HQ613D-B, which was recently cleared by the U.S. Food and Drug Administration for sale in the U.S.

Why Purchase the Report?

  • To visualize the global digital breast tomosynthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the digital breast tomosynthesis market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global digital breast tomosynthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of breast cancer
      • 4.1.1.2. Advancements in the devices
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with the devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. PESTLE Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. 2D/3D Combination systems *
    • 6.2.1. Introduction
  • 6.3. Standalone 3D Systems

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.2. Market Attractiveness Index, By Application
  • 7.3. Screenings*
    • 7.3.1. Introduction
    • 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.4. Diagnostic

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Centers
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Fujifilm *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. GE Healthcare
  • 11.3. GMM (IMS Giotto)
  • 11.4. Hologic, Inc
  • 11.5. Planmeca (Planmed)
  • 11.6. Siemens Healthineers
  • 11.7. Philips Healthcare
  • 11.8. Afga Healthcare
  • 11.9. Trivitron Healthcare
  • 11.10. Carestream Health (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us